112641-20-0

Usage

Uses

Used in Pharmaceutical Industry:
2-Fluoro-3-(trifluoromethyl)benzaldehyde is used as a key intermediate in the synthesis of various pharmaceutical compounds, particularly in the development of novel curcumin analogs with mono-carbonyl. These analogs have potential applications in the treatment of various diseases due to their enhanced bioavailability and improved pharmacological properties compared to the parent compound, curcumin.
Used in Chemical Synthesis:
2-Fluoro-3-(trifluoromethyl)benzaldehyde serves as a valuable building block in the synthesis of a wide range of organic compounds, including pharmaceuticals, agrochemicals, and specialty chemicals. Its unique chemical properties, such as the presence of fluorine and trifluoromethyl groups, contribute to the diversity and reactivity of the synthesized products, making it a useful compound in the field of organic chemistry.
Used in Material Science:
The compound's unique chemical structure and properties also make it a potential candidate for the development of new materials with specific properties, such as improved thermal stability, chemical resistance, or electronic properties. Researchers in material science may explore its potential applications in the design and synthesis of novel materials for various industrial applications.

InChI:InChI=1/C8H4F4O/c9-7-5(4-13)2-1-3-6(7)8(10,11)12/h1-4H

Upstream product

• 392-85-8 1-fluoro-2-trifluoromethylbenzene 
• 93-61-8 N-methyl-N-phenylformamide 

Downstream Products

• 1026352-56-6 (E)-3-(2-Fluoro-3-trifluoromethyl-phenyl)-acrylic acid ethyl ester 
• 237069-83-9 FLUORO(TRIFLUOROMETHYL)-CINNAMIC ACID 
• 869478-14-8 4-(2-formyl-6-trifluoromethyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 342808-25-7 3,5-Bis-(2-fluoro-3-α,α,α-trifluoromethylbenzylidene)-piperidin-4-one 
• 258346-73-5 1-(2-fluoro-3-trifluoromethylphenyl)-1,3-pentanedione 
• 885694-00-8 7-(trifluoromethyl)-1H-indazole 
• 918900-51-3 2-fluoro-5-nitro-3-(trifluoromethyl)benzaldehyde 
• 1018785-60-8 (2E,5E)-2,5-bis[2-fluoro-3-(trifluoromethyl)benzylidene]cyclopentanone 
• 1192716-59-8 2-(tert-butylsulfanyl)-3-(trifluoromethyl)benzenaldehyde 
• 581072-16-4 2-fluoro-3-trifluoromethyl-benzaldehyde oxime 
• 1393363-57-9 tert-butyl (E)-3-[2'-fluoro-3'-(trifluoromethyl)phenyl]-prop-2-enoate 
• 1393364-03-8 tert-butyl (3R,αR)-3-[N-benzyl-N-(α-methylbenzyl)amino]-3-[2'-fluoro-3'-(trifluoromethyl)phenyl]propanoate 
• 1393363-71-7 tert-butyl (3S,αR)-3-[N-benzyl-N-(α-methylbenzyl)amino]-3-[2'-fluoro-3'-(trifluoromethyl)phenyl]propanoate 
• 1422961-62-3 3-pyridylmethyl 7-(2-fluoro-3-trifluoromethylphenyl)-5-methyl-2,3,4,7-tetrahydrothieno[3,2-b]pyridin-6-carboxylate-1,1-dioxide 

Relevant academic research and scientific papers

(Oxime)carbamoyl fatty acid amide hydrolase inhibitors

The present invention relates to novel oxime carbamyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase. These pharmaceutical compositions are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase including, but not limited to, neuropathic pain, emesis, anxiety, altering feeding behaviors, movement disorders, glaucoma, brain injury, and cardiovascular disease.

Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions thereof

There are described compounds of Formula I, in which R1, R2, R3 and R4 are as defined in the specification,R5 is alkyl optionally interrupted by an amide group and optionally substituted by halogen or by a carboxy or a heterocyclic group,X is -O-, -NR-, -S(O)m1, or a bond,Z is hydrogen or together with R forms a bond,R is hydrogen, alkyl or together with Z forms a bond,R6 is a 5 or 6 membered unsaturated nitrogen containing heterocyclic ring, optionally fused to a phenyl ring and optionally substituted by one or more of oxo, hydroxy, alkyl, -(CH2)n1NH2, alkoxy, phenyl or -COOH,and when X is -NR- or -S(O)m1-, R6 may in addition be hydrogen or a group -CH2CH2NH2, -CH2CH2-het. or NHC(=NH)NH2,when X is -O-, R6 may also be a group -NH2, -C(=O) (CH2)nNH2, -CH2CH2NR14R15 or CH2CH2OCH2CH2NR14R15,when X is -NR-, -S(O)m1-, or a bond, R6 may also be hydrogen or a group -C(=NR12)NHR13,R13 and R14 may be hydrogen or alkyl,R12 is hydrogen, alkylcarbonyl, nitrile or hydroxy,R15 is hydrogen or a group R11,m and m1 are each 0, 1 or 2,n is 0 or 1,n1 is an integer from 0 to 6, and pharmaceutically acceptable salts, esters, amides, analogues and protected derivatives thereof.